Business briefs: Celgene

Share this article:

Celgene's Pomalyst (pomalidomide), an oral treatment for relapsed and refractory multiple myeloma, was approved by the FDA this week. It is the second such treatment approved for the blood cancer in the past seven months with Onyx's Kyprolis (carfilzomib) approved last July. Approval was based on response rate while clinical benefit (i.e. survival, symptoms) has not been verified by regulators. The treatment will only be available to patients through a restricted distribution program, Pomalyst REMS. Analysts forecast Pomalyst sales to reach $1.1 billion in 2017.

Share this article:

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.